NICE is clear: cannabis-based medicinal products are not recommended for managing chronic pain in adults under its current guideline. That does not mean pain patients are wrong to ask questions, and it does not mean every private specialist assessment is identical to an NHS guideline summary. It does mean chronic pain should never be presented as automatic access to medical cannabis.
This guide is for UK patients and carers searching questions like “can you get medical cannabis for chronic pain in the UK?”, “does NICE recommend medical cannabis for pain?”, “can a private clinic prescribe medical cannabis for pain?”, and “is chronic pain enough to qualify?”. It explains the difference between official NICE guidance, NHS prescribing reality, and a private specialist discussion.
It is not medical advice and it cannot decide whether any treatment is suitable for you. That decision sits with a specialist prescriber who can review your diagnosis, records, previous treatments, medicines, side effects, mental health, and risk factors.
If you are new to the wider route, start with the MCPH patient guide. If you are checking the broader access question, the medical cannabis qualifying conditions guide can help you understand whether you may qualify for a specialist assessment, but it is not the final clinical decision. If your main concern is safety, read about medical cannabis side effects and medication interactions as well.
The short answer
NICE’s cannabis-based medicinal products guideline says not to offer several cannabis-based medicines for chronic pain in adults. It also says not to offer CBD for chronic pain outside a clinical trial.
The NHS medical cannabis page gives a similar public message: there is some evidence that medical cannabis can help certain types of pain, but the evidence is not strong enough to recommend it for pain relief. It says pain prescribing may happen in clinical trial contexts.
For patients, the practical meaning is this:
- chronic pain is a real and serious reason to seek care;
- NICE does not currently recommend cannabis-based medicinal products as a chronic pain treatment;
- a diagnosis of chronic pain does not automatically mean a person can access medical cannabis;
- private specialist assessment is still a clinical assessment, not a self-selection route;
- safety screening matters, especially side effects, interactions, impairment, mental health history, and previous treatment response.
The SEO-short answer is the same as the patient answer: NICE does not recommend medical cannabis for chronic pain, but UK private specialist assessment is a separate clinical process and should be explained without promising access.
What NICE NG144 says about chronic pain
NICE NG144 is the main NICE guideline on cannabis-based medicinal products. In its chronic pain section, NICE says not to offer nabilone, dronabinol, THC, or a CBD and THC combination to manage chronic pain in adults. It also says not to offer CBD for chronic pain in adults unless this is part of a clinical trial.
That wording is stronger than “not enough information yet”. It is a recommendation against offering those cannabis-based options for chronic pain in the NICE guidance context.
NICE also includes a narrow continuation point for adults who had already started cannabis-based medicinal products for chronic pain in the NHS before the November 2019 guidance. That is not a new access route. It is about how existing NHS treatment should be reviewed and continued or stopped with the NHS clinician.
How NICE NG193 fits in
NICE NG193 is the broader chronic pain guideline. It covers chronic pain in people over 16 and explains the difference between chronic primary pain and chronic secondary pain.
Chronic primary pain is pain with no clear underlying condition that fully explains it, or pain whose impact is out of proportion to observable injury or disease. Chronic secondary pain is pain where an underlying condition adequately accounts for the pain or its impact. NICE also recognises that both can exist at the same time.
That distinction matters because chronic pain is not one single clinical situation. A person with neuropathic pain, fibromyalgia, endometriosis-related pain, arthritis, MS-related pain, or pain after injury may all be using the phrase “chronic pain”, but their assessment, risk factors, and treatment history can be very different.
NG193 does not create a separate cannabis recommendation. For cannabis-based medicinal products, it points readers back to NG144.
NHS guidance and private specialist assessment are not the same thing
NHS guidance is cautious because the evidence base for chronic pain is limited, products are often unlicensed, and NHS prescribing has to follow national commissioning and governance rules. NHS England says there are no licensed cannabis-based medicinal products for pain and that the evidence is not sufficiently developed.
Private specialist prescribing exists in UK law, but that does not make chronic pain a simple checklist. NHS England also says prescribing is a clinical decision that should consider the patient’s condition, other medicines, evidence for the indication, safety, and the suitability of licensed medicines.
So the balanced version is:
- NICE does not recommend cannabis-based medicinal products for chronic pain;
- private specialists may assess individual patients within professional and legal rules;
- the prescriber must still justify suitability, safety, monitoring, and the choice of any medicine;
- patients should not assume that a pain diagnosis alone decides the outcome.
That is patient-led access realism: patients can ask informed questions, but the clinical decision remains with the prescriber.
What patients can prepare for a discussion
If you are considering a specialist conversation about chronic pain, useful preparation is usually about clarity, not persuasion.
You may want to gather:
- the diagnosis or working diagnosis you have been given;
- a brief pain history, including when it started and how it affects daily life;
- relevant hospital letters, clinic letters, or Summary Care Record information from your GP surgery;
- medicines and treatments you have already tried, including why they were stopped or why they were unsuitable;
- current prescription medicines, over-the-counter medicines, supplements, alcohol use, and any non-prescribed cannabinoid use;
- major physical and mental health history, including previous adverse reactions to cannabis or THC.
This is not about building a case that forces a decision. It helps the prescriber understand risk, previous treatment response, and whether any discussion of cannabis-based medicine is clinically appropriate.
If you are still at the records stage, MCPH has a guide on how to request your Summary Care Record and a separate explainer on what counts as trying two treatments.
Safety issues are not a footnote
For chronic pain patients, safety can be as important as evidence. Medical cannabis products can cause side effects, and THC-containing products can affect alertness, mood, anxiety, perception, and impairment. The NHS also notes that CBD and THC can affect how other medicines work.
This is especially relevant if you take opioids, gabapentinoids, benzodiazepines, antidepressants, sleep medicines, antipsychotics, medicines for seizures, medicines with liver monitoring, or anything else that affects the central nervous system. Do not stop, switch, or reduce existing medicines without clinical advice.
Mental health screening also matters. A prescriber may ask about psychosis, schizophrenia history, bipolar or mania risk, severe depression, suicidality, substance-use concerns, and previous adverse cannabis reactions. For more context, read MCPH’s guide to medical cannabis and mental health screening and THC side effects and impairment.
What this means in plain English
If you have chronic pain, NICE’s position is not vague: it does not recommend cannabis-based medicinal products for managing chronic pain in adults, and CBD for chronic pain is only supported in a clinical trial context.
At the same time, a patient can still ask careful questions about private specialist assessment, especially when other treatments have not helped, caused problems, or been unsuitable. The answer may still be no. It may be that another treatment, review, or pain-management approach is more appropriate. It may also be that a specialist wants more records or a clearer picture of risk before making any decision.
The useful question is not “Does chronic pain qualify me?” It is: “What does my diagnosis, treatment history, risk profile, and current medicines mean for a specialist assessment?”
FAQ
Does NICE recommend medical cannabis for chronic pain?
No. NICE NG144 says not to offer several cannabis-based medicinal products to manage chronic pain in adults, and not to offer CBD for chronic pain outside a clinical trial.
Can you get medical cannabis for chronic pain in the UK?
Some private specialists may assess individual chronic pain patients under UK prescribing rules, but that is not the same as saying chronic pain automatically qualifies someone. The assessment still depends on diagnosis, previous treatments, records, risks, current medicines, and clinical judgement.
Does that mean no chronic pain patient can ever discuss medical cannabis privately?
No. It means NICE does not recommend it for chronic pain, and any private discussion still has to be an individual specialist assessment. A private appointment should not be treated as a promised route to treatment.
Is chronic pain enough on its own?
No. Chronic pain alone should not be framed as automatic access. A prescriber would need to consider the diagnosis, previous treatments, current medicines, risks, evidence, and whether a cannabis-based medicinal product is suitable at all.
What if other treatments have not helped?
That can be relevant history, but it does not decide suitability by itself. It is one part of a wider clinical assessment.
Why do private clinics discuss chronic pain if NICE says no?
NICE guidance is highly important, especially for NHS practice, but private specialist prescribing still works through individual clinical assessment and professional responsibility. A clinic should be clear about evidence limits, safety, previous treatments and why any medicine is being considered.
What does NICE say about CBD for chronic pain?
NICE says not to offer CBD for chronic pain in adults unless this is part of a clinical trial. Shop-bought CBD is also not the same thing as a prescribed cannabis-based medicinal product.
Can this article tell me what product or dose to ask for?
No. Product, form, dose, route, monitoring, and whether treatment is suitable belong with a specialist prescriber. Patients can raise concerns and questions, but this guide does not recommend a product or dose.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NICE. Chronic pain in over 16s: recommendations, NG193. https://www.nice.org.uk/guidance/ng193/chapter/Recommendations
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
Cover image brief: cover-brief.md.
